royale therapeutics limited
royale therapeutics limited Company Information
Company Number
10548266
Website
-Registered Address
2nd floor regis house, 45 king william street, london, EC4R 9AN
Industry
Research and experimental development on biotechnology
Telephone
-
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
penelope shihab 100%
royale therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of ROYALE THERAPEUTICS LIMITED at £238.9k based on a Turnover of £179.3k and 1.33x industry multiple (adjusted for size and gross margin).
royale therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of ROYALE THERAPEUTICS LIMITED at £0 based on an EBITDA of £-232.3k and a 5.47x industry multiple (adjusted for size and gross margin).
royale therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of ROYALE THERAPEUTICS LIMITED at £0 based on Net Assets of £-232.5k and 0.51x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Royale Therapeutics Limited Overview
Royale Therapeutics Limited is a dissolved company that was located in london, EC4R 9AN with a Companies House number of 10548266. It operated in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 2017, it's largest shareholder was penelope shihab with a 100% stake. The last turnover for Royale Therapeutics Limited was estimated at £179.3k.
Upgrade for unlimited company reports & a free credit check
Royale Therapeutics Limited Health Check
Pomanda's financial health check has awarded Royale Therapeutics Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
6 Weak
Size
annual sales of £179.3k, make it smaller than the average company (£2.1m)
- Royale Therapeutics Limited
£2.1m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Royale Therapeutics Limited
- - Industry AVG
Production
with a gross margin of 53.7%, this company has a comparable cost of product (53.7%)
- Royale Therapeutics Limited
53.7% - Industry AVG
Profitability
an operating margin of -129.5% make it less profitable than the average company (0.7%)
- Royale Therapeutics Limited
0.7% - Industry AVG
Employees
with 2 employees, this is below the industry average (26)
2 - Royale Therapeutics Limited
26 - Industry AVG
Pay Structure
on an average salary of £62.1k, the company has an equivalent pay structure (£62.1k)
- Royale Therapeutics Limited
£62.1k - Industry AVG
Efficiency
resulting in sales per employee of £89.7k, this is less efficient (£115.4k)
- Royale Therapeutics Limited
£115.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Royale Therapeutics Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 104 days, this is slower than average (60 days)
- Royale Therapeutics Limited
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Royale Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (43 weeks)
0 weeks - Royale Therapeutics Limited
43 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 853.7%, this is a higher level of debt than the average (51.8%)
853.7% - Royale Therapeutics Limited
51.8% - Industry AVG
ROYALE THERAPEUTICS LIMITED financials
Royale Therapeutics Limited's latest turnover from January 2018 is estimated at £179.3 thousand and the company has net assets of -£232.5 thousand. According to their latest financial statements, Royale Therapeutics Limited has 2 employees and maintains cash reserves of £3.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jan 2018 | |
|---|---|
| Turnover | |
| Other Income Or Grants | |
| Cost Of Sales | |
| Gross Profit | |
| Admin Expenses | |
| Operating Profit | |
| Interest Payable | |
| Interest Receivable | |
| Pre-Tax Profit | |
| Tax | |
| Profit After Tax | |
| Dividends Paid | |
| Retained Profit | |
| Employee Costs | |
| Number Of Employees | 2 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jan 2018 | |
|---|---|
| Tangible Assets | 0 |
| Intangible Assets | 0 |
| Investments & Other | 0 |
| Debtors (Due After 1 year) | 0 |
| Total Fixed Assets | 0 |
| Stock & work in progress | 0 |
| Trade Debtors | 0 |
| Group Debtors | 0 |
| Misc Debtors | 27,581 |
| Cash | 3,272 |
| misc current assets | 0 |
| total current assets | 30,853 |
| total assets | 30,853 |
| Bank overdraft | 9,662 |
| Bank loan | 0 |
| Trade Creditors | 23,753 |
| Group/Directors Accounts | 0 |
| other short term finances | 0 |
| hp & lease commitments | 0 |
| other current liabilities | 229,976 |
| total current liabilities | 263,391 |
| loans | 0 |
| hp & lease commitments | 0 |
| Accruals and Deferred Income | 0 |
| other liabilities | 0 |
| provisions | 0 |
| total long term liabilities | 0 |
| total liabilities | 263,391 |
| net assets | -232,538 |
| total shareholders funds | -232,538 |
| Jan 2018 | |
|---|---|
| Operating Activities | |
| Operating Profit | |
| Depreciation | 0 |
| Amortisation | 0 |
| Tax | |
| Stock | 0 |
| Debtors | 27,581 |
| Creditors | 23,753 |
| Accruals and Deferred Income | 229,976 |
| Deferred Taxes & Provisions | 0 |
| Cash flow from operations | |
| Investing Activities | |
| capital expenditure | |
| Change in Investments | 0 |
| cash flow from investments | |
| Financing Activities | |
| Bank loans | 0 |
| Group/Directors Accounts | 0 |
| Other Short Term Loans | 0 |
| Long term loans | 0 |
| Hire Purchase and Lease Commitments | 0 |
| other long term liabilities | 0 |
| share issue | |
| interest | |
| cash flow from financing | |
| cash and cash equivalents | |
| cash | 3,272 |
| overdraft | 9,662 |
| change in cash | -6,390 |
royale therapeutics limited Credit Report and Business Information
Royale Therapeutics Limited Competitor Analysis
Perform a competitor analysis for royale therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other undefined companies, companies in EC4R area or any other competitors across 12 key performance metrics.
royale therapeutics limited Ownership
ROYALE THERAPEUTICS LIMITED group structure
Royale Therapeutics Limited has no subsidiary companies.
Ultimate parent company
ROYALE THERAPEUTICS LIMITED
10548266
royale therapeutics limited directors
Royale Therapeutics Limited currently has 3 directors. The longest serving directors include Ms Penelope Shihab (Jan 2017) and Mr John McKinley (Jan 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Penelope Shihab | Jordan | 50 years | Jan 2017 | - | Director |
| Mr John McKinley | 70 years | Jan 2017 | - | Director | |
| Professor Christopher Lowe | England | 78 years | Jan 2017 | - | Director |
P&L
January 2018turnover
179.3k
0%
operating profit
-232.3k
0%
gross margin
53.8%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2018net assets
-232.5k
0%
total assets
30.9k
0%
cash
3.3k
0%
net assets
Total assets minus all liabilities
royale therapeutics limited company details
company number
10548266
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
January 2017
age
7
incorporated
UK
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
last accounts submitted
January 2018
address
2nd floor regis house, 45 king william street, london, EC4R 9AN
accountant
-
auditor
-
royale therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to royale therapeutics limited.
royale therapeutics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
